The analysis of other tumor suppressors codeleted with PTEN showed that PML was deleted in 31% of mCRPC, but was intact in localized prostate cancers; furthermore, PML and PTEN were codeleted in ~20% of cases, in association with metastatic disease; PTEN and PML loss negatively impacted on the survival of prostate cancer patients. Here, PML is linked to metastatic neoplasm.